In a recent study, more than 40% of patients with relapsed or refractory germ cell tumors experienced a clinical benefit with cabozantinib.

The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

The ethics of direct-to-consumer ads from pharmaceutical companies is being debated as the FDA looks towards possibly banning them altogether.

Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or ...

Capivasertib+abiraterone was associated with more symptomatic AEs but did not impact HRQoL in patients with PTEN-deficient ...

Findings presented at the 2026 ASCO GU Symposium show that combinatorial therapies may provide new treatment options for patients with renal cell carcinoma or muscle-invasive bladder cancer.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...

Gemcitabine intravesical system+intravenous cetrelimab did not improve bladder-intact event-free survival or OS for pts with MIBC who did not receive radical cystectomy.

Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...

In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.

Patients who receive durvalumab plus tremelimumab for resected RCC report worse quality of life compared to those who receive active monitoring.